Suppliers / Zhejiang Bamboo Pharmaceuticals Co.,Ltd

Zhejiang Bamboo Pharmaceuticals Co.,Ltd

China 3 employees Updated 9 July 2026

Zhejiang Bamboo Pharmaceuticals Co.,Ltd is an API manufacturer based in China. It holds 6 active US drug master files across a filed portfolio of 5 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 27 September 2024 as VAI.

6
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 27 September 2024 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Shaoxing, China Not on file
China, China 3019684157

What they file, and where

Molecule Regulators Docs
Pregabalin US FDA 2
Benzocaine US FDA 1
Gabapentin US FDA 1
Levocarnitine US FDA 1
Tranexamic Acid US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Bamboo Pharmaceuticals Co.,Ltd comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 27 September 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates